Latest News

  • TapImmune Appoints John Bonfiglio as Strategic Adv...

    Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise SEATTLE, Feb. 25, 2015 - TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John...

    Read more

  • TapImmune Appoints Patrick D. Yeramian, MD, Consul...

    SEATTLE, Feb. 23, 2015 – TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased...

    Read more

  • TapImmune to Present at the 3rd Annual Sachs Bio P...

    TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015 Seattle, WA – February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company...

    Read more

  • TapImmune Selects PCG Advisory Group for Investor ...

    TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations Seattle, WA & NY, NY – February 19, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company...

    Read more

  • Positive Phase 1 Immune Responses in All Evaluable...

    Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers  January 12, 2015, Seattle...

    Read more

  • TapImmune, Inc. Announces $1,464,000 Million Regis...

    Exercise in Full of Strategically Designed Warrant Package Would Result in $34,404,000 in Additional Funding Seattle, January 12, 2015 — TapImmune, Inc. (the “Company”), (otcqb:TPIV),...

    Read more

  • TapImmune CEO Discusses Company’s Clinical P...

    In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement from phase 1 to phase 2 trials SEATTLE, Nov. 24, 2014 /PRNewswire/ — TapImmune, Inc....

    Read more

  • TapImmune Announces Phase II Clinical Trials Colla...

    Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design SEATTLE, WASHINGTON, November 18, 2014 — TapImmune, Inc. (OTCQB: TPIV), is...

    Read more

  • TapImmune Provides Update on PolyStart™ Vaccine ...

    Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox.   SEATTLE, WASHINGTON,...

    Read more

  • Tapimmune, a Biotech Company Focused on Stimulatin...

    TapImmune, a biotech company focused on stimulating the body’s own immune system to fight cancer. Please listen to the interview with host Eric Michaels of eHealth Radio Network and TapImmune CEO...

    Read more

  • National Breast Cancer Awareness Month...

    A personal perspective from Dr Glynn Wilson, Chairman & CEO, TapImmune National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer...

    Read more

  • TapImmune CEO Provides Update on Corporate Activit...

    I am pleased to provide this update to existing shareholders and interested potential shareholders SEATTLE–(BUSINESS WIRE)– TapImmune is a clinical-stage immunotherapy company...

    Read more

  • SeeThruEquity Issues Company Update on TapImmune H...

    SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate...

    Read more

  • TapImmune Releases Positive Interim Data on Phase ...

    All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of...

    Read more

  • SeeThruEquity to Hold Fall Microcap Investor Confe...

    Conference Being Held at Convene Times Square in Midtown NEW YORK / ACCESSWIRE / September 8, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm...

    Read more

  • TapImmune Inc to Present at SeeThruEquity Microcap...

    Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday...

    Read more

  • TapImmune Inc to Present at 16th Annual Rodman �...

    Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics...

    Read more

  • SeeThruEquity Issues Update Note on TapImmune High...

    New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it...

    Read more

  • TapImmune, Inc. Announces $2 Million Registered Di...

    SEATTLE, Aug 11, 2014 (BUSINESS WIRE) — TapImmune, Inc. (the "Company"), (otcqb:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for...

    Read more

  • TapImmune’s New Clinical Trial in Advanced S...

    SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide...

    Read more